Illumina, Inc. (NASDAQ:ILMN) Issues FY17 Earnings Guidance
Illumina, Inc. (NASDAQ:ILMN) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $3.60-3.70 for the period, compared to the Thomson Reuters consensus estimate of $3.63. The company issued revenue guidance of +12% to ~$2.69 billion, compared to the consensus revenue estimate of $2.66 billion.
A number of equities research analysts have weighed in on ILMN shares. Vetr downgraded Illumina from a strong-buy rating to a buy rating and set a $197.84 price objective on the stock. in a report on Wednesday, May 31st. Zacks Investment Research upgraded shares of Illumina from a hold rating to a buy rating and set a $195.00 target price for the company in a research report on Thursday, July 27th. Canaccord Genuity upgraded shares of Illumina from a hold rating to a buy rating and upped their target price for the company from $170.00 to $215.00 in a research report on Monday, August 7th. First Analysis upgraded shares of Illumina from an underweight rating to an equal weight rating and set a $176.00 target price for the company in a research report on Wednesday, August 2nd. Finally, Barclays PLC reiterated an equal weight rating and set a $150.00 target price on shares of Illumina in a research report on Wednesday. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. Illumina presently has an average rating of Hold and a consensus price target of $177.01.
Shares of Illumina, Inc. (NASDAQ ILMN) traded down 0.21% during midday trading on Friday, reaching $194.25. 695,985 shares of the company traded hands. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $199.95. The company has a 50-day moving average of $179.63 and a 200 day moving average of $173.73. The firm has a market capitalization of $28.36 billion, a PE ratio of 38.97 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662 million for the quarter, compared to the consensus estimate of $642.38 million. During the same quarter last year, the firm posted $0.86 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. On average, equities analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current year.
In related news, Director Jay T. Flatley sold 3,320 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $180.55, for a total value of $599,426.00. Following the sale, the director now owns 519,176 shares in the company, valued at $93,737,226.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $175.53, for a total transaction of $2,632,950.00. Following the transaction, the director now owns 534,176 shares in the company, valued at approximately $93,763,913.28. The disclosure for this sale can be found here. Insiders have sold 134,010 shares of company stock worth $23,946,015 in the last ninety days. Insiders own 1.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://theolympiareport.com/2017/08/12/illumina-inc-nasdaqilmn-releases-fy17-earnings-guidance-updated.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.